Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

Seasoned pharma & biotech executive joins the Board of mid-stage clinical company

Lausanne, SWITZERLAND and Cambridge, MA, USA, May 20, 2019 – Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, today announces the appointment of Dr Eric Yuen to its Board of Directors.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...